141 related articles for article (PubMed ID: 21494838)
1. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.
Kantarjian HM; Padmanabhan S; Stock W; Tallman MS; Curt GA; Li J; Osmukhina A; Wu K; Huszar D; Borthukar G; Faderl S; Garcia-Manero G; Kadia T; Sankhala K; Odenike O; Altman JK; Minden M
Invest New Drugs; 2012 Jun; 30(3):1107-15. PubMed ID: 21494838
[TBL] [Abstract][Full Text] [Related]
2. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors.
Infante JR; Kurzrock R; Spratlin J; Burris HA; Eckhardt SG; Li J; Wu K; Skolnik JM; Hylander-Gans L; Osmukhina A; Huszar D; Herbst RS
Cancer Chemother Pharmacol; 2012 Jan; 69(1):165-72. PubMed ID: 21638123
[TBL] [Abstract][Full Text] [Related]
3. Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.
Jones R; Vuky J; Elliott T; Mead G; Arranz JA; Chester J; Chowdhury S; Dudek AZ; Müller-Mattheis V; Grimm MO; Gschwend JE; Wülfing C; Albers P; Li J; Osmukhina A; Skolnik J; Hudes G
Invest New Drugs; 2013 Aug; 31(4):1001-7. PubMed ID: 23329066
[TBL] [Abstract][Full Text] [Related]
4. A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.
Gerecitano JF; Stephenson JJ; Lewis NL; Osmukhina A; Li J; Wu K; You Z; Huszar D; Skolnik JM; Schwartz GK
Invest New Drugs; 2013 Apr; 31(2):355-62. PubMed ID: 22615058
[TBL] [Abstract][Full Text] [Related]
5. Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors.
Esaki T; Seto T; Ariyama H; Arita S; Fujimoto C; Tsukasa K; Kometani T; Nosaki K; Hirai F; Yagawa K
Arch Drug Inf; 2011 Jun; 4(2):23-31. PubMed ID: 21765863
[TBL] [Abstract][Full Text] [Related]
6. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
7. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.
Kantarjian HM; Jabbour EJ; Garcia-Manero G; Kadia TM; DiNardo CD; Daver NG; Borthakur G; Jain N; Waukau JB; Kwari MI; Ravandi F; Anderson BD; Iizuka K; Jin C; Zhang C; Plunkett WK
Cancer; 2019 May; 125(10):1665-1673. PubMed ID: 30668890
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.
Khoury HJ; Garcia-Manero G; Borthakur G; Kadia T; Foudray MC; Arellano M; Langston A; Bethelmie-Bryan B; Rush S; Litwiler K; Karan S; Simmons H; Marcus AI; Ptaszynski M; Kantarjian H
Cancer; 2012 Jul; 118(14):3556-64. PubMed ID: 22139909
[TBL] [Abstract][Full Text] [Related]
10. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Lancet JE; Roboz GJ; Cripe LD; Michelson GC; Fox JA; Leavitt RD; Chen T; Hawtin R; Craig AR; Ravandi F; Maris MB; Stuart RK; Karp JE
Haematologica; 2015 Feb; 100(2):231-7. PubMed ID: 25381131
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
Burris HA; Jones SF; Williams DD; Kathman SJ; Hodge JP; Pandite L; Ho PT; Boerner SA; Lorusso P
Invest New Drugs; 2011 Jun; 29(3):467-72. PubMed ID: 20069338
[TBL] [Abstract][Full Text] [Related]
12. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
13. The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study.
O'Connor OA; Gerecitano J; Van Deventer H; Hainsworth J; Zullo KM; Saikali K; Seroogy J; Wolff A; Escandón R
Leuk Lymphoma; 2015; 56(9):2585-91. PubMed ID: 25665464
[TBL] [Abstract][Full Text] [Related]
14. First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer.
Chung V; Heath EI; Schelman WR; Johnson BM; Kirby LC; Lynch KM; Botbyl JD; Lampkin TA; Holen KD
Cancer Chemother Pharmacol; 2012 Mar; 69(3):733-41. PubMed ID: 22020315
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.
Schimmer AD; Raza A; Carter TH; Claxton D; Erba H; DeAngelo DJ; Tallman MS; Goard C; Borthakur G
PLoS One; 2014; 9(10):e108694. PubMed ID: 25285531
[TBL] [Abstract][Full Text] [Related]
16. A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.
Souid AK; Dubowy RL; Ingle AM; Conlan MG; Sun J; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2010 Dec; 55(7):1323-8. PubMed ID: 20712019
[TBL] [Abstract][Full Text] [Related]
17. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.
Holen KD; Belani CP; Wilding G; Ramalingam S; Volkman JL; Ramanathan RK; Vasist LS; Bowen CJ; Hodge JP; Dar MM; Ho PT
Cancer Chemother Pharmacol; 2011 Feb; 67(2):447-54. PubMed ID: 20461380
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.
Uy GL; Assouline S; Young AM; Blotner S; Higgins B; Chen LC; Yee K
Invest New Drugs; 2020 Oct; 38(5):1430-1441. PubMed ID: 32020437
[TBL] [Abstract][Full Text] [Related]
19. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
Gomez HL; Philco M; Pimentel P; Kiyan M; Monsalvo ML; Conlan MG; Saikali KG; Chen MM; Seroogy JJ; Wolff AA; Escandon RD
Anticancer Drugs; 2012 Mar; 23(3):335-41. PubMed ID: 22123335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
